转移性肾癌细胞因子疗法的研究进展  

Development of Cytokine Therapy for Metastatic Renal Cell Carcinoma

作　　者：杜晓博[1] 王毅[1] 李建军[1] 钱坤[1] 彭潋[1] 

机构地区：[1]南华大学附属第二医院泌尿外科,湖南衡阳421001

出　　处：《现代生物医学进展》2012年第9期1763-1765,共3页Progress in Modern Biomedicine

摘　　要：转移性肾癌(mRCC)对放疗、化疗均不敏感,虽然靶向治疗为转移性肾癌的治疗提供了新的治疗方案,但免疫疗法一直作为治疗转移性肾癌的基础疗法。在过去的20年中,研究者也一直在研究新的免疫疗法,研究方向趋向于研究各种细胞因子,其中最主要的有IFN-α和IL-2两种,二者可以明显提高患者的生存时间。但是转移性肾癌的细胞因子疗法仍需进一步优化,本文总结了使用细胞因子治疗转移性肾癌的Ⅲ期临床试验,以期为转移性肾癌细胞因子疗法的合理选择提供参考。Metastatic renal cell carcinoma（mRCC） is not sensitive to radiotherapy and chemotherapy.Although the targeted therapy allows a new option for the treatment protocol of mRCC,the immune therapy is still the basic therapy.During the last two decades,the metastatic RCC has long been a testing ground for novel immunotherapy research,and researchers have tended to study various cytokines,mainly including interferon-α（IFN-α） and interleukin-2（IL-2） which can obviously increase the survival time of patients.But further study to optimize the antitumor effect of the cytokine therapy on metastatic RCC is needed.This essay intends to provide references for the selection of mRCC cytokine therapy,by summarizing the Stage III clinical trials which has employed cytokine therapy.

关 键 词：转移性肾癌 免疫疗法 细胞因子 IFN-Α IL-2 

分 类 号：R737.11[医药卫生—肿瘤]